The GPCR Epstein-Barr virus-induced gene 2 (EBI2, also known as GPR183) is activated by oxysterols and plays a pivotal role in the regulation of B cell migration during immune responses. While the molecular basis of agonist binding has been addressed in several studies, the concept of biased agonism of the EBI2 receptor has not been explored.
Introduction
Seven transmembrane segment (7TM) receptors, also known as GPCRs, represent the largest family of integral membrane proteins in the human genome with approximately 800 members. These receptors control most aspects of human physiology via their interaction with a broad range of chemically distinct endogenous ligands (Schwartz et al., 2006) and are, therefore, of great interest as targets in drug development (Rosenbaum et al., 2009) . The largest subfamily, the class A rhodopsin-like 7TM receptors, contains several important drug targets as approximately 35% of all currently marketed drugs bind to this subfamily of receptors (Overington et al., 2006) .
The Epstein-Barr virus-induced gene 2 receptor (EBI2; also known as GPR183) belongs to the class A 7TM receptors and was identified in 1993 as the most up-regulated gene in Burkitt lymphoma cells after Epstein-Barr virus infection (Birkenbach et al., 1993) . It plays a crucial role during immunological responses as it regulates B cell migration (Gatto et al., 2009; Pereira et al., 2009 ) and positioning in secondary lymphoid tissues (Gatto and Brink, 2013; Gatto et al., 2011; guided by endogenous oxysterol (Hannedouche et al., 2011; Li et al., 2016) . EBI2 was initially described as a heterotrimeric G protein subunit Gi,α-signalling receptor . At present, multiple downstream pathways have been described including mobilization of intracellular calcium, activation of MAPKs and proliferation; most of these are pertussis toxin-dependent indicating Gi-mediated signalling (Hannedouche et al., 2011; Liu et al., 2011; Benned-Jensen et al., 2011; . However, G proteinindependent activation via β-arrestin recruitment has also been demonstrated (Hannedouche et al., 2011; Liu et al., 2011; Benned-Jensen et al., 2013) . Among the oxysterol ligands identified, the most potent one, 7α, , displays potencies ranging from 200 nM in β-arrestin recruitment to 0.1 nM in GTPγS binding (Daugvilaite et al., 2014) . The closest human homologues of EBI2 are GPR17 and GPR18, yet these three receptors share very little functional overlap except for the overall lipid nature of the endogenous ligands (Kohno et al., 2006; Benned-Jensen and Rosenkilde, 2010; Nørregaard et al., 2011) .
As illustrated by the signalling pathways of EBI2, 7TM receptors are able to signal both through G proteindependent and -independent pathways. Preferential signalling through one over another pathway for a certain ligand-receptor pair is known as biased agonism or functional selectivity (Kenakin, 2012; Steen et al., 2014) . Notably, biased ligands are already being developed (Sivertsen et al., 2013) and some are undergoing clinical trials, for example, the μ receptor ligand TRV130, with the aim of developing safer and more efficacious drugs (Soergel et al., 2013; .
In addition to endogenous and exogenous ligands, the signalling of 7TM receptors may be regulated by ions, most notably by zinc and sodium. In the latter case, it has been known for decades that sodium ions function as negative allosteric modulators of many 7TM receptors, but the mechanism has remained elusive (Costa et al., 1990; Gao and Ijzerman, 2000; Schwartz and Holst, 2007; Selent et al., 2010; Kenakin, 2012; Katritch et al., 2014) . However, the recent crystal structure of the δ receptor has provided significant new insights into the role of sodium and its coordination in the ligand binding pocket. In this receptor, one of the key residues for sodium binding is an asparagine (Asn) located at position III:11/3.35 (N131) in transmembrane (TM)-III, that functions as a gatekeeper for biased agonism. NaCl acts as a negative allosteric modulator of agonist binding by directly interacting with this residue, as evident by the dose-dependent decrease in affinity upon co-incubation with NaCl . This effect disappeared upon mutation of N131 to alanine and valine; two mutations that at the same time resulted in increased constitutive β-arrestin-mediated signalling, but not increased G protein-signalling, indicating β-arrestinbiased receptor signalling .
Here, we examined the role of the equivalent residue in EBI2, Asn 114 : an evolutionary conserved residue that directly faces the main binding crevice. While previous work has suggested that this residue is involved directly in ligand binding (Zhang et al., 2012) , our data indicate that Asn 114 plays a more indirect role by (1) regulating the equilibrium between GPCR conformations and conformations that preferably bind β-arrestins and (2) being part of an allosteric sodium ion binding site between residues in TM-I, -II, -III, -VI and -VII.
Methods
Transfection and cell culture CHO cells were grown in RPMI1640 medium containing 10% FBS, 2 mM glutamine, 180 u·mL À1 penicillin and 45 μg·mL À1 streptomycin (PenStrep) at 5% CO 2 and 37°C. Stably transfected CHO Flp-In cells were grown in the same medium that also contained 600 μg·mL À1 hygromycin. The CHO-K1
EA-arrestin2 cell line was grown in F-12 HAM medium containing 10% FBS, PenStrep and 250 μg·mL À1 hygromycin.
a 20 min incubation on a shaker at room temperature, cold ligand at various concentrations was added followed by the addition of [ 3 H]-7α,25-OHC to a final concentration of 10 nM. The plates were sealed and incubated at room temperature overnight. The following day, the plates were spun down at 500 × g for 5 min and counted in a TopCounter (PerkinElmer Life Sciences). Homologous membrane binding studies were performed with various concentrations of NaCl (0, 10, 100 and 400 mM).
GTPγS binding assay
Measurement of GTPγS binding to CHO Flp-In M1-EBI2 WT or pcDNA5 membranes in the presence of 7α,25-OHC at various concentrations was performed as described previously (Benned-Jensen et al., 2012) . Briefly, 10 μg of membrane preparation was incubated for 30 min in the presence of the agonist and 1 nM [ 35 S]-GTPγS. WGA PVT SPA beads were subsequently added (2.8 mg·mL À1 ) followed by a 30 min incubation. After centrifugation (500 × g, 5 min) the amount of GTPγS binding was measured using a TopCounter. Non-specific binding was determined by adding 40 μM unlabelled GTPγS.
β-arrestin recruitment
The recruitment of β-arrestin2 was measured using the PathHunter β-arrestin assay (DiscoveRx, Birmingham, UK). cDNA encoding M1-EBI2 WT was fused to the ProLink C-terminal protein tag and the small fragment of β-galactosidase and cloned into pcDNA3.1+. Assays were performed in a CHO-K1 EA-arrestin cell line stably expressing β-arrestin2 coupled to the β-gal large fragment. Cells were seeded at 20 000 per well in 96-well plates and transfected the following day with 50 ng DNA using FuGENE6 reagent (0.15 μL per well). Forty-eight hours after transfection, cells were stimulated with various concentrations of 7α,25-OHC, 7α,27-OHC, 25-hydroxycholesterol (25-OHC), 7α-dihydroxycholesterol (7α-OHC) for 90 min. β-Arrestin2 recruitment was detected as β-gal activity 60 min after addition of chemiluminescent substrate.
ELISA and immunocytochemistry
HEK293 cells were transiently transfected with the indicated FLAG-tagged receptor constructs as described above. Fortyeight hours after transfection, the cells were fixed in 4% formaldehyde for 10 min, washed three times in Tris-buffered saline (TBS) and blocked for 30 min with TBS containing 2% BSA. Subsequently, the cells were incubated with mouse anti-FLAG M1 antibody at 2 μg·mL À1 for 2 h in TBS supplemented with 1% BSA and 1 mM CaCl 2 . After three washes in TBS containing 1% BSA and 1 mM CaCl 2 , the cells were incubated for 1 h with goat anti-mouse horseradish peroxidase-conjugated antibody diluted 1:1000 in the same buffer as the primary antibody. Following washing, the immune reactivity was determined by addition of 3,3 0 ,5,5 0 -tetramethylbenzidine according to the manufacturer's instructions. All steps were carried out at room temperature, and all constructs were tested at least three times in quadruplicates. For immunocytochemistry, a similar protocol was used with Alexa Fluor® 488 secondary antibody. Confocal imaging was performed using a LSM780 microscope equipped with a 1.4 numerical aperture 63× lens.
Live cell imaging
CHO-K1 cells were transiently transfected with the EBI2 WT and N114A receptors N-terminally tagged with pHTomato, a red phluorin. As pHTomato only fluoresces at neutral pH (Li and Tsien, 2012) , it selectively indicates cell surface expressed receptors, due to the acidic pH of the endosomal system. Cells were seeded out at 150 000 cells per well in 6-well plates and transfected the following day with a total amount of 1 μg DNA (0.7 μg of pHT-tagged receptor and 0.3 μg of β-arrestin2-eGFP) using Lipofectamine 2000 reagent (10 μL per well). Twenty-four hours after transfection, live imaging was performed at 37°C using a LSM780 microscope and an open imaging chamber. For stimulation experiments, cells were stimulated with 10 μM of 7α,25-OHC after four frames. Fluorescence was captured at 0.1 Hz for 10 min.
Molecular modelling
To assess the structural basis for the observed allosteric modulation by sodium, homology modelling of EBI2 was performed using 'Internal Coordinate Mechanics' (Molsoft L.L.C., San Diego, CA, USA). The structure of the closely related proteinase-activated receptor 1 (PAR1) (PDB 3VW7), solved to 2.2 Å resolution, was obtained from the RCSB protein data bank and used as a template. Crystallization water and co-crystallized molecules were deleted, the structure was converted to an internal coordinate mechanics (ICM) object, thereby assigning protein atom types optimizing hydrogens and His, Pro, Asn, Gly and Cys side chain conformations and the receptor model was subjected to 300 steps of Cartesian minimization in order to yield a structure in a low-energy conformation. Alignments of currently available crystal structures featuring evidence for sodium binding were based on the Zero End-gap Global Alignment algorithm (Abagyan et al., 1997) . The sequence of the human EBI2 receptor was obtained from UniProt (The UniProt Consortium, 2015).
Cellular distribution assay
HEK293 cells were seeded on poly-lysine treated coverslips in 6-well plates at 500 000 cells per well. The following day, the cells were transfected with FLAG-tagged EBI2 WT, N114A, N114V, pcDNA 3.1 at 150 ng per well using Lipofectamine2000 reagent and subsequently incubated in growth medium at 10% CO 2 and 37°C. Twenty-four hours after transfection, the cells were washed once in TBS and fixed in 3.7% paraformaldehyde for 15 min. After three washes in TBS, the specimens were blocked with 2% BSA in TBS for 20 min. To specifically label the receptors residing at the cell surface, the coverslips were incubated with mouse M1 anti-FLAG antibody (Sigma-Aldrich), 2 μg·mL À1 , in TBS containing 1% BSA and 1 mM CaCl 2 for 1 h. Subsequently, the cells were washed three times in TBS containing 1 mM CaCl 2 and incubated with goat Alexa Fluor 488-conjugated anti-mouse (Molecular Probes Invitrogen) diluted 1:1000 for 30 min. After three washes, the cells were permeabilized by incubation with 1% BSA, 1 mM CaCl 2 and 0.2% saponin in TBS (permeabilization buffer) for 20 min. To specifically label the population of receptors residing intracellularly, the specimens were incubated in permeabilization buffer containing mouse anti-FLAG antibody (Sigma-Aldrich) at 2 μg·mL À1 for 1 h. Following three washes, the coverslips were incubated with goat Alexa Fluor 568-conjugated antimouse IgG antibodies (Molecular Probes Invitrogen) diluted 1:1000 in permeabilization buffer for 30 min. The specimens were finally mounted in fluorescence mounting medium (Dako), using nail polish as a sealant, after three washes. Images were obtained using 20× objective on Olympus IX70 inverted microscope.
Statistical analysis and calculations
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Statistical analysis, α factor (allosteric EC 50 shift model) (Gentry et al., 2015) , IC 50 (log inhibitor vs. response fit) and receptor density (B max ) (one site-homologous fit) calculations were performed using GraphPad prism. For the allosteric shift model, we analysed the effect of NaCl on the displacement of radioligand by cold 7α,25-OHC.
B max results are given in counts·min
À1
. This was recalculated to fmol·mg
. The specific activity of [ 3 H]-7α,25-OHC equals 969.8 GBq·mmol
, and a counter efficiency of 50% was taken into account.
K i was calculated using Cheng-Prusoff equation (Prusoff and Cheng, 1973) , K D = 0.45 nM was used for this calculation; this was taken from the EBI2 deorphanization paper (Liu et al., 2011 (Li and Tsien, 2012) and rat β-arrestin2 GFP wild type (WT) was from Addgene (plasmid # 35411). Goat anti-goat IgG H&L (Alexa Fluor 488) was purchased from Abcam (Cambridge, UK) (ab150129). Goat Alexa Fluor 568-and 488-conjugated anti-mouse IgG antibodies (Molecular Probes Invitrogen, Glasgow, UK).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 .
Results
Using a mutagenic approach, we previously identified a selection of residues important for 7α,25-OHC-mediated EBI2 activation (Benned-Jensen et al., 2012) ( Figure 1A) . Notably, despite using several assays to characterize thẽ 25 EBI2 mutants -most of which pointed towards the main binding pocket -we did not find any mutation that led to biased agonism. As previously mentioned, a newly discovered sodium-coordinating residue in the δ receptor, an Asn (N131), functions as a gatekeeper for biased agonism . The equivalent residue in EBI2 (N114) was not part of our initial mutagenic analysis, and we therefore decided to examine N114 with regard to its potential control of EBI2 signalling. This residue is located at position III:11/3.35 in the lower part of TM-III, close to Goat anti-mouse Alexa-Fluor 488-conjugated IgG antibody was used to specifically label receptors residing at the cell surface. Scale bar represents 7 μm. Student's t-test was used for statistical analysis ****P < 0.05. All experiments were performed in duplicate in five independent experiments.
residues important for 7α,25-OHC binding and thus could putatively be vital for EBI2 activation ( Figure 1A, B) . To examine the functional role of N114, we initially mutated it to an alanine (EBI2 N114A) using a FLAG-tagged EBI2 WT construct as a backbone. The mutant was well expressed at the cell surface in HEK cells as determined by ELISA ( Figure 1C ), albeit at lower levels than EBI2 WT (approximately 50% of WT, Figure 1D ). Furthermore, we determined the cellular distribution of the receptor constructs by staining cell surface and intracellular receptors with two different antibodies. Corroborating the ELISA data, the cell surface population of EBI2 N114A was lower than the WT receptor, which is probably due to a larger intracellular retention of this construct. Hence, the ratio of cell surface/intracellular receptors is smaller for EBI2 N114A compared with EBI2 WT (Supporting Information Figure S1 ). Figure 2B and Table 1 ). These data indicate that N114 is not essential for oxysterol binding to EBI2, as previously suggested, but indeed important for activation of the receptor (Zhang et al., 2012) . Given the observation that the equivalent residue in the δ receptor functions as an efficacy switch between G protein and β-arrestin signalling, we next examined whether EBI2 N114A was still able to recruit β-arrestin. Indeed, we observed a dose-dependent recruitment in CHO cells expressing EBI2 N114A ( Figure 2C ). Although it was not as efficacious as in EBI2 WT cells (~70% activation, Figure 2C inset) it was more potent (EC 50 value of 2 nM for EBI2 N114A compared with 36.8 nM for EBI2 WT). This observation may be explained by the mutant's larger intracellular receptor reserve (Supporting Information Figure S1 ). In addition to 7α,25-OHC, we also tested 7α,27-OHC, 25-OHC and 7α-OHC in the β-arrestin recruitment assay. Interestingly, all the oxysterols recruited β-arrestin in EBI2 N114A-expressing cells, but only 7α,25-OHC and 7α,27-OHC recruited β-arrestin in their WT counterparts (Supporting Information Figure S2 ) with EC 50 values of 39.8 and 174 nM respectively. This correlates well with EC 50 values from the GTPγS recruitment assay where 7α,25-OHC has the highest potency of all the oxysterols (EC 50 value of 140 pM) while 7α,27-OHC is the second most potent (EC 50 value of 1.3 nM). In accordance, 25-OHC and 7α-OHC, which did not recruit β-arrestin in EBI2 WT-expressing cells, displayed even lower potencies (EC 50 values of 127 and 96 nM respectively) (Liu et al., 2011) . These findings further confirmed that EBI2 N114A is biased towards recruiting β-arrestin. Furthermore, basal recruitment of β-arrestin was significantly higher for N114A compared with the WT receptor ( Figure 2C ) which is equivalent to what is observed for the δ receptor . Using live cell imaging, we confirmed that The data were normalized to maximal recruitment levels by 7α,25-OHC for each receptor and presented as % (mean ± SEM). Inset shows data normalized to maximal β-arrestin2 recruitment by 7α,25-OHC for EBI2 WT receptor and presented as % (mean ± SEM). Student's t-test was used to compare basal β-arrestin2 recruitment on EBI2 WT and N114A (*P < 0.05). All experiments were performed in duplicate in five independent experiments.
Biased agonism of the EBI2 receptor (GPR183) BJP both WT and mutant cells were able to recruit β-arrestin. Thus, we observed a robust recruitment of eGFP-tagged β-arrestin to the cell membrane of 7α,25-OHC-stimulated cells co-transfected with EBI2 WT or N114A ( Figure 3A ). There was no apparent difference in the kinetics as β-arrestin recruitment was fast in both cases, occurring within 20 s to 1 min. However, in agreement with our functional data ( Figure 2B ), we regularly observed β-arrestin-clusters in ligand-untreated EBI2 N114 transfected cells, but never in EBI2 WT cells (Figure 3 , 0 min). We also sought to examine the binding and signalling properties of another N114 mutant, N114V, as the equivalent substitution in the δ receptor preferentially signals through a β-arrestin-mediated pathway . However, the cell surface expression of this mutant was very low (Table 1) , and we did not observe any radioligand binding or β-arrestin recruitment in cells expressing EBI2 N114V.
Thus, collectively, our data indicate that N114 at position III:11/3.35 does not have an influence on oxysterol binding to EBI2 but rather increases basal β-arrestin recruitment and plays a vital role in G protein activation. (Liu et al., 2011)] and potencies of 7α,25-OHC (depicted as LogEC 50 ) in two different functional assays (GTPγS and β-arrestin recruitment). The data are presented as mean ± SEM, and the number of independent experiments is indicated (n). ND, not determined; N/A, not applicable. 
Allosteric modulation by sodium
Sodium acts as an allosteric modulator in several GPCRs including the α 2A -adrenoceptor, the adenosine A 2A receptor, the dopamine D 2 receptor and, as described above, the δ receptor . Besides serving as a gatekeeper for biased agonism, residue N131 in the δ receptor also participates in the binding of a sodium ion, which in turn functions as a negative allosteric modulator of ligand binding (Costa et al., 1990; Gao and Ijzerman, 2000; Schwartz and Holst, 2007; Selent et al., 2010; Kenakin, 2012; Katritch et al., 2014) . We therefore assessed the effect of sodium on 7α,25-OHC binding to EBI2 WT or EBI2 N114A. To do this, membrane binding studies were performed with various concentrations of NaCl (0, 10, 100, 400 mM). For EBI2 WT, the apparent affinity was decreased, albeit moderately, with increasing NaCl concentrations, whereas this was not the case for EBI2 N114A. Thus, while the ratio between the K i values of EBI2 WT and EBI2 N114 was~1.8 at 0 mM NaCl, it dose-dependently increased to~5.3 at 400 mM NaCl ( Figure 4C , for more information, see Supporting Information Table S1 ). We also calculated the α factor using the standard allosteric model (Christopoulos and Kenakin, 2002) . This confirmed that sodium indeed acts as a negative allosteric modulator on EBI2 WT (α factor = 0.15; Logα = -1.36; SEM: 0.27) exhibiting an affinity of approximately 43 mM (LogKb = À1.4; SEM: 0.37). However, it had a modest positive cooperativity effect on EBI2 N114A (α factor = 2.1; Logα = 0.32; SEM: 0.43), thus indicating that sodium exerts its function at least partly via this residue. Finally, we observed a significantly higher dissociation rate for EBI2 WT as compared with N114A (À0.063 ± 0.0012 and À0.013 ± 0.0098 min À1 respectively, P < 0.05 by Student's t-test). In the presence of 100 mM sodium, there was a tendency for a faster oxysterol dissociation from EBI2 WT (À0.069 ± 0.009 min À1 ) compared with EBI2 N114A (À0.041 ± 0.01 min À1 ), but this did not reach statistical significance (P > 0.05, by Student's t-test). Collectively, our data indicate that sodium is able to modulate the binding of oxysterols to EBI2 by acting as a negative allosteric modulator via N114.
Homology modelling and structural analysis
In order to investigate the structural basis for the observed allosteric modulation by sodium, we generated a homology model of EBI2 based on the X-ray crystal structure of the PAR1 receptor (PDB 3VW7), for which sodium binding has been observed ( Figure 5 ). In general, protein-bound sodium ions are typically coordinated by five oxygen atoms that originate either from amino acids or water molecules with a bond length of~2.4 Å (Zheng et al., 2008) . An Asn at position 3.35 is a conserved member of the sodium binding residues in the γ-and δ-branch of class a 7TM receptors . A structural comparison of 11 residues in TM-I, -II, -III, -VI and -VII that have previously been shown to form an allosteric sodium binding site indicates a high conservation level of sodium binding residues in EBI2. Most key residues in the first coordination shell, such as D77, N114 and D304, are conserved in EBI2. Residues in the second and watercoordinating sphere are highly similar compared with other receptors with evidence for an allosteric sodium binding site. The only major difference, S118 is replaced by G118 in EBI2, which indicates that the corresponding coordinating oxygen atom might be supplied in a different fashion in EBI2 compared with other sodium-binding 7TM receptors ( Figure 5 ). In conclusion, the structural arrangement in the homology model and the functional data support the evidence for an allosteric sodium binding pocket in EBI2.
Discussion
In the present paper, we have investigated the importance of residue N114 for the signalling profile of EBI2. Located at Biased agonism of the EBI2 receptor (GPR183) BJP
Figure 5
Structural comparison of the allosteric sodium binding site in EBI2 (green) and PAR1 (dark grey) receptors. The PAR1-based homology model of EBI2 built in the Molsoft ICM programme was superimposed onto the sodium-bound high-resolution crystal structure of PAR1 (PDB 3VW7). Sodium ions from the PAR1 crystal structure (blue) and water molecules (red) are shown by transparent spheres and smaller solid spheres. TM-I was omitted for clarity. A sequence comparison of the 16 sodium pocket residues is shown for currently available crystal structures featuring evidence of sodium ion binding. Key: OR, opioid receptor; A2aAR, alpha2a adrenoceptor; B1AR, beta1 adrenoceptor. V Daugvilaite et al. position III:11/3.35 in the middle of TM-III, this residue faces the main binding crevice and several important microswitches (Nygaard et al., 2009; Rosenkilde et al., 2010) ( Figure 1 ). In agreement with this central position, we here show that it is functionally important in several ways. First, mutating N114 to an alanine abolished G protein signalling by oxysterols (Figure 2A ) but at the same time increased the potency of β-arrestin recruitment ( Figure 2B ). This indicates that this residue plays a key role in modulating the signalling profile of EBI2. Secondly, our data suggest that N114 functions as a sodium-coordinating residue, as the negative allosteric effect of this ion was abolished in the N114A mutant (Figure 4 ). Of note, this is in close agreement with the role of the equivalent residue in the δ receptor . Indeed, this mechanism may be relatively common as Asn is the most frequently found amino acid at this position (29% of 7TM receptors) and the second most frequent amino acid is serine (21%), which also is capable of coordinating sodium (Mirzadegan et al., 2003) . In line with this, the two additional residues that are part of the coordination triad in the δ receptor, a serine at III:15/3.39 and an aspartate at II:10/2.50, are also highly conserved at 75 and 94% respectively. This increases to 86 and 97% when receptors not containing an Asn at position III:11/3.35 are excluded. Thus, in most receptors, if one coordinating residue is present so are the other two. Interestingly, EBI2 is an exception as it contains a glycine rather than a serine at III:15/3.39 ( Figure 5) . While the precise functional outcome remains elusive, it is interesting to note that several molecular pharmacological differences exist between EBI2 and the δ receptor, especially with regard to position II:10/ 2.50. Specifically, alanine substitution of II:10/2.50 in EBI2 abolishes both G protein activation and β-arrestin recruitment by oxysterols (Benned-Jensen et al., 2012; Zhang et al., 2012) . In contrast, the equivalent substitution in the δ receptors only abolishes naltrindole-induced G protein activation but not β-arrestin recruitment . Thus, the mutation functions as an efficacy switch in the latter receptor but not in EBI2. Furthermore, we have previously shown that substituting II:10/2.50 with an arginine does not affect the EBI2 activation by oxysterols. In fact, this charge-reversing mutation even increases the specific agonist binding and is able to rescue another binding-deficient mutant (Benned-Jensen and Benned-Jensen et al., 2012) . Thus, the functional discrepancies between these receptors may putatively be explained the structural differences in the sodium triad. Such differences indeed exist, as evident from the crystal structure of PAR1 (Zhang et al., 2012) . Thus, in comparison to the δ receptor, the Na + pocket is shifted 1.5 Å towards TM-IV in this receptor.
BJP
In general, position III:11/3.35 has been shown to be a functional 'hot-spot'. It is well known that a mutation of the equivalent residue in the AT 1 receptor (N111G) and CXCR4 receptor (N119S) results in constitutive activation and that the residue in addition functions as an anchor site for binding of the endogenous agonist in the former receptor (Noda et al., 1996; Berchiche et al., 2007) . Interestingly, a recent molecular dynamics simulation suggested that N111 keeps the AT 2 receptor in an inactive conformation through hydrogen bonds with the Asp at II:10 (Cabana et al., 2015) . Moreover, as suggested by a new crystal structure, this probably also involves a sodium ion (Zhang et al., 2015) .
Evidence supporting the importance of allosteric action and biased agonism for developing safer and more efficacious drugs has emerged in recent years (Jacobson et al., 2015) . A study on μ receptors suggests that there is shared allosteric binding site for lipophilic allosteric ligands (Bartuzi et al., 2015) and that these opioid receptor ligands could be a safer option for treating pain, depression or immune disorders. An illustrative example of biased agonism and specific receptor targeting is found in the subfamily of dopamine receptors. Dysfunction or dysregulation of these receptors is a hallmark of many psychiatric diseases and why targeting the dopamine system remains a cornerstone in treatment regimens (Park et al., 2016) . However, as dopamine receptors play a key role in, for example, controlling movement, these drugs come with notable side effects. Recent data suggest that selectively targeting either G protein-coupled or β-arrestin-regulated pathways may limit side effects or improve efficacy. For instance, while lithium has been used for the treatment of a range of neurological disorders for decades, its mechanism of action has remained elusive until recently. Intriguingly, it was shown that lithium disrupts a complex composed of Akt, protein phosphatase 2A and β-arrestin2 and its beneficial effects on behaviour were disrupted in β-arrestin2 knockout animals (Beaulieu et al., 2008) . Also, a group of β-arrestin-selective D 2 receptor ligands were still potent anti-psychotics but lacked the motor side effects induced by non-biased ligands. Notably, the anti-psychotic effects were absent in animals lacking β-arrestin (Allen et al., 2011) . Biased agonism is not only restricted to rhodopsin-like receptors as this has also been shown for the PTH receptor. This receptor normally regulates both bone formation and bone loss through activation of different cellular targets. However, a PTH receptor that is truncated signals through arrestin only and induces bone formation but not bone loss in vivo (Gesty-Palmer et al., 2009) , which is why biased PTH receptor agonists may be of therapeutic value in osteoporosis. Insights into the mechanism of receptor bias may help develop more efficacious drugs with fewer side effects. For EBI2, this could involve selective manipulation of N114. conducted all in vitro experiments; A.W.S. provided the radioligand and the experimental design for the competition binding experiments; M.L. and T.F. designed and conducted the homology modelling; and V.D., M.M.R. and T.B.J. wrote the manuscript.
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https://doi.org/10.1111/bph.13801 Figure S1 Receptor cellular localization. Rows represent (A) EBI2 WT, (B) EBI2 N114A, (C) EBI2 N114V, (D) pcDNA 3.1 transiently transfected HEK293 cells. Left column: merged picture shows cell membrane (green colour) and intracellular receptor (red colour) localization. Right column presents quantification of fluorescence intensity for each receptor on the cell membrane and intracellularly. Experiment was performed five times. Scale bar represents 10 uM. Figure S2 β-arrestin recrtuitment by oxysterols. 7α,25-OHC, 7α,27-OHC, 25-OHC, 7α-OHC -induced β-arrestin2 recruitment in β-arrestin-β-galactosidase-expressing CHO cells transiently transfected with PK1 tagged human EBI2 WT(A) and EBI2 N114A(B). The data were normalized to maximal recruitment levels for 7α,25-OHC on EBI2 WT (A) and EBI2 N114A (B) and presented in % as means ± S.E. Table S1 Sodium ion acts as an allosteric modulator of 7α,25-OHC binding. The half maximal inhibitory concentration (IC 50 determined using GraphPad Prism equation: log (inhibitor) vs. response fit) and inhibitory (Ki constant calculated using Cheng-Prusoff equation (William H. Prusoff, 1973) , with Kd = 0.45 nM (Liu et al., 2011 
